hdm1002 + itraconazole

HDM1002 + itraconazole refers to the concurrent administration of **HDM1002**, an orally active, small molecule, highly selective full agonist of the **glucagon-like peptide-1 (GLP-1) receptor**, and **itraconazole**, a triazole antifungal medication. HDM1002 is developed as a novel, non-peptide GLP-1 receptor agonist for weight management and type 2 diabetes, with demonstrated linear pharmacokinetics, safety, and dose-dependent efficacy in clinical trials. Itraconazole is a CYP3A4 inhibitor, and its co-administration is commonly used in drug-drug interaction studies to assess metabolic pathways for small molecule drug candidates. There are no approved or branded combination products for HDM1002 + itraconazole; their combined mention is primarily in the context of pharmacokinetic interaction studies. HDM1002 is independently developed by Hangzhou Zhongmei Huadong Pharmaceutical, a subsidiary of Huadong Medicine, and is currently in Phase 2/3 development for type 2 diabetes and obesity. Itraconazole is generic and widely manufactured by multiple pharmaceutical companies.